Cytek Biosciences Inc
CTKB4.620USD
+0.080+1.76%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
590.74MMarket Cap
LossP/E TTM
More Details of Cytek Biosciences Inc Company
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Cytek Biosciences Inc Info
Ticker SymbolCTKB
Company nameCytek Biosciences Inc
IPO dateJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Number of employees648
Security typeOrdinary Share
Fiscal year-endJul 23
Address47215 Lakeview Boulevard
CityFREMONT
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94538
Phone18779229835
Websitehttps://cytekbio.com
Ticker SymbolCTKB
IPO dateJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Company Executives of Cytek Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
10.18K
+27.27%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
By RegionUSD
Name
Revenue
Proportion
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
Shareholding Stats
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
Other
68.45%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
Other
68.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
20.84%
Individual Investor
9.28%
Hedge Fund
7.26%
Pension Fund
1.17%
Research Firm
1.00%
Bank and Trust
0.37%
Family Office
0.11%
Venture Capital
0.09%
Other
30.76%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
315
75.48M
59.03%
-10.81M
2025Q2
324
88.51M
69.57%
-10.34M
2025Q1
332
90.47M
71.35%
-13.48M
2024Q4
323
90.06M
70.25%
-11.48M
2024Q3
303
87.47M
66.52%
-16.26M
2024Q2
288
88.67M
67.45%
-13.39M
2024Q1
284
98.75M
75.24%
-12.70M
2023Q4
276
96.90M
74.11%
-15.57M
2023Q3
266
97.16M
71.81%
-17.75M
2023Q2
259
98.92M
72.71%
-3.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.73M
2.15%
+42.92K
+1.60%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
0.24%
Royce Quant Small-Cap Quality Value ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
iShares S&P Small-Cap 600 Value ETF
0.05%
SPDR S&P 600 Small Cap Value ETF
0.05%
Principal U.S. Small-Cap ETF
0.04%
iShares Biotechnology ETF
0.04%
Proshares Ultra Smallcap 600
0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.03%
View more
Invesco S&P SmallCap Health Care ETF
Proportion0.24%
Royce Quant Small-Cap Quality Value ETF
Proportion0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.05%
iShares S&P Small-Cap 600 Value ETF
Proportion0.05%
SPDR S&P 600 Small Cap Value ETF
Proportion0.05%
Principal U.S. Small-Cap ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Proshares Ultra Smallcap 600
Proportion0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
